Gritstone Bio Basic EPS 2017-2024 | GRTSQ
Gritstone Bio basic eps from 2017 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Gritstone Bio Annual Basic EPS |
| 2023 |
$-1.20 |
| 2022 |
$-1.32 |
| 2021 |
$-0.95 |
| 2020 |
$-2.79 |
| 2019 |
$-2.81 |
| 2018 |
$-7.26 |
| 2017 |
$-20.70 |
| 2016 |
$-11.21 |
| Gritstone Bio Quarterly Basic EPS |
| 2024-06-30 |
$-0.16 |
| 2024-03-31 |
$-0.34 |
| 2023-12-31 |
$-0.26 |
| 2023-09-30 |
$-0.33 |
| 2023-06-30 |
$-0.31 |
| 2023-03-31 |
$-0.30 |
| 2022-12-31 |
$-0.29 |
| 2022-09-30 |
$-0.35 |
| 2022-06-30 |
$-0.34 |
| 2022-03-31 |
$-0.34 |
| 2021-12-31 |
$-0.36 |
| 2021-09-30 |
$-0.36 |
| 2021-06-30 |
$-0.33 |
| 2021-03-31 |
$0.10 |
| 2020-12-31 |
$-0.70 |
| 2020-09-30 |
$-0.69 |
| 2020-06-30 |
$-0.69 |
| 2020-03-31 |
$-0.71 |
| 2019-12-31 |
$-0.79 |
| 2019-09-30 |
$-0.77 |
| 2019-06-30 |
$-0.63 |
| 2019-03-31 |
$-0.62 |
| 2018-12-31 |
$12.94 |
| 2018-09-30 |
$-7.60 |
| 2018-06-30 |
$-6.57 |
| 2018-03-31 |
$-6.03 |
| 2017-12-31 |
|
| 2017-09-30 |
$-4.59 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
